Skip to main content

Autoinflammatory

Overview of the VEXAS Syndrome A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome. https://t.co/45qeSb14GB https://t.co/2mHEHh7BmU
Dr. John Cush @RheumNow( View Tweet )

Hmmm Really? (7.11.2025)

Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?

Read Article
Referral of 304 suspected autoinflammatory Dz (SAID) to a UK national centre for primarily adult SAID in 2022, 121 (39.5%) were diagnosed with SAID, w/ half of these having monogenic Dz. Median Dx delay was 2 to 6 yrs, worse in late-onset SAID. https://t.co/x8VOFyjuVA https://t.co/3R2HdYUlSg
Dr. John Cush @RheumNow( View Tweet )

Overview of the VEXAS Syndrome

A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.

Read Article
Japanese cohort study compared 12 pts w/ Stills Dz or intravascular lymphoma. Stills pt had significantly higher ferritin and IL-18 levels and IVL pts had significantly higher sIL-2R levels. https://t.co/Ecd6vNJTc4 https://t.co/KdEcpDeskA
Dr. John Cush @RheumNow( View Tweet )
FDA approves new drug for MAS in Still's disease. Gamifant (emapalumab-lzsg) is interferon gamma (IFNγ)–blocking Ab approved For HLH, now for use in adults & children w/ Still's Dz complicated by Macrophage Activation Syndrome. https://t.co/3div1fktWU https://t.co/VvSkuEoki5
Dr. John Cush @RheumNow( View Tweet )
Pregnancy outcomes in autoinflammatory disease To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual https://t.co/oQ7A2bnDmO
Dr. John Cush @RheumNow( View Tweet )

Nurse-Led Treat-to-Target Clinics

EurekAlert!

New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.

Read Article

EULAR 2025 – Day 4 Report

Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following.

Read Article

Pregnancy outcomes in autoinflammatory disease

EurekAlert!

To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual congress of EULAR – showcased findings from 97 women with an

Read Article
EULAR FMF recommendations 2025: still emphasis on colchicine adherence to maximal dose +/- bDMARDs if needed for control +/- csDMARDs for residual chronic MSK involvement new: consider tapering bDMARD if remission >6mo See the treatment algorithm below⬇️ #EULAR2025 @RheumNow https://t.co/Hy6DOKzfUL
David Liew @drdavidliew( View Tweet )
FMF #Recommendations 🔺️Start Colchicine in All (& continue for confirmed pts) 🔺️Single or divided dose, depend on adherence & tolerance 🔺️Max dose 2 mg children, 3 mg adults 🔺️if failure: add IL1i (6 RCT) (2 for IL6i) 🔺️Add c or bDMARd if MSK #EULAR2025 @RheumNow https://t.co/fPyQrLbb6S
Nelly ZIADE 🍀 @Nellziade( View Tweet )
FMF #Recommendations During attack: 🔺️No use of increasing Colchicine 🔺️No use for corticosteroids and opioid 🔺️Use NSAIDs #EULAR2025 @RheumNow https://t.co/jJjWJra7yr
Nelly ZIADE 🍀 @Nellziade( View Tweet )
FMF #Recommendations #Colchicine can be fatal 🔺️Monitor regularly #EULAR2025 @RheumNow https://t.co/VJZYPaBrvE
Nelly ZIADE 🍀 @Nellziade( View Tweet )
FMF #Recommendations #Colchicine can be fatal 🔺️Beware of drug interactions 🔺️Mostly statins in adults 🔺️Macrolides in children #EULAR2025 @RheumNow https://t.co/SYGLpAJXFu
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Procalcitonin can be used in the monitoring of infection, but is also high in Stills disease. 89 AOSD pts showed pts w high PCT had more pleuritis, MAS,^LFTs, & correlated w/ Dz activity, CRP, LDH, hi ferritin & normalized w bDMARD Rx. #EULAR2025 abstr #POS1118 https://t.co/NpRA9optd3
Dr. John Cush @RheumNow( View Tweet )
"H Syndrome" review of 23 French pts. Autoinflammatory dz due to variants of SLC29A3 gene. Multisystem histiocytic lymphoproliferative disorder of young adults- skin 2/3, sensorineural hearing loss, fever w/ endo & autoimmune dz. Best responses w IL6 inhib. #EULAR2025 Abst https://t.co/F7NGI4TkJS
Dr. John Cush @RheumNow( View Tweet )
The definition of MAS. MAS is secondary HLH. Other causes of secondary HLH are infections, malignancy and iatrogenic. Georgin-Lavialle S @RheumNow #EULAR2025 https://t.co/CpB78JBlVJ
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Total serum IL 18 can help instead of CDC42 or NLCR4 genetic testing in #MAS Several monogentic mutations in primary HLH- these panels can be available.. #EULAR2025 @RheumNow

Bella Mehta @bella_mehta( View Tweet )

Age of onset is really important when thinking about #MAS Primary HLH more frequent in pediatric population. But can continue to adulthood. #EULAR2025 @RheumNow https://t.co/J7xmTiQiwr
Bella Mehta @bella_mehta( View Tweet )
MAS can be triggered by infections in VEXAS syndrome. The threshold is reached leading to a hyperinflammatory state Georgin-Lavialle S @rheumnow #EULAR2025 https://t.co/NKLL75rOgP
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Management of HLH/MAS and modes of action of advanced therapies Jessica Manson @RheumNow #EULAR2025 https://t.co/Op3u53ZXeK
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Stabilize the pts with HLH with steroids when still trying to figure out the diagnosis of #HLH/ #MAS Many drugs can be used...but important to balance infection risk with immunosuppression These are critical pts. Be vigilant.. #EULAR2025 @RheumNow https://t.co/id4ae3SWtj
Bella Mehta @bella_mehta( View Tweet )
Closing the care divide in #JIA treatment plenary session Overall theme in #EULAR2025 is everyone talking about AI and digital health on day 1 Biologics have changed the game! @RheumNow https://t.co/qDqbz8JApe
Bella Mehta @bella_mehta( View Tweet )
Treatment of MAS, or the bête noire in Still's disease, presented at the Plenary session by Peter Nigrovic #Plenary room #EULAR2025 @RheumNow https://t.co/S4SG2VflNg
Nelly ZIADE 🍀 @Nellziade( View Tweet )
×